LON:CLIN - Clinigen Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 740
  • Forecasted Upside: -5.37 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 782
▲ +3.5 (0.45%)

This chart shows the closing price for CLIN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clinigen Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLIN

Analyst Price Target is GBX 740
▼ -5.37% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Clinigen Group in the last 3 months. The average price target is GBX 740, with a high forecast of GBX 860 and a low forecast of GBX 650. The average price target represents a -5.37% upside from the last price of GBX 782.

This chart shows the closing price for CLIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Clinigen Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2021Peel HuntReiterated RatingHoldGBX 650
12/1/2021Liberum CapitalReiterated RatingBuyGBX 800
11/5/2021Liberum CapitalLower Price TargetBuyGBX 886 ➝ GBX 800
10/21/2021Royal Bank of CanadaReiterated RatingOutperformGBX 860
8/25/2021Shore CapitalReiterated RatingBuy
8/5/2021Peel HuntReiterated RatingHoldGBX 650
8/5/2021Peel HuntReiterated RatingHoldGBX 650
7/13/2021Shore CapitalReiterated RatingBuy
6/18/2021Liberum CapitalLower Price TargetBuyGBX 1,050 ➝ GBX 886
4/6/2021Liberum CapitalReiterated RatingBuy
9/29/2020Peel HuntReiterated RatingHoldGBX 820
9/29/2020Peel HuntReiterated RatingHoldGBX 820
7/23/2020Liberum CapitalReiterated RatingBuy
7/23/2020Peel HuntDowngradeHoldGBX 1,280 ➝ GBX 820
7/14/2020Royal Bank of CanadaReiterated RatingOutperformGBX 1,500 ➝ GBX 1,300
7/13/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/15/2020Liberum CapitalReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/28/2020Liberum CapitalBoost Price TargetBuyGBX 850 ➝ GBX 1,050
5/14/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/16/2020Liberum CapitalReiterated RatingBuyGBX 850
4/16/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/24/2020Liberum CapitalReiterated RatingBuy
3/20/2020Royal Bank of CanadaReiterated RatingTop pickGBX 1,600 ➝ GBX 1,500
3/18/2020Liberum CapitalUpgradeBuy
3/11/2020Liberum CapitalUpgradeBuy
3/5/2020Peel HuntReiterated RatingBuy
3/3/2020Royal Bank of CanadaReiterated RatingTop pick
2/26/2020Liberum CapitalUpgradeHoldGBX 790
2/25/2020Liberum CapitalDowngradeSell
2/24/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/16/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalBoost Price TargetHoldGBX 1,000 ➝ GBX 1,035
1/10/2020Peel HuntReiterated RatingBuy
12/16/2019Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/15/2019Liberum CapitalReiterated RatingHold
11/6/2019Liberum CapitalReiterated RatingHoldGBX 1,000
11/4/2019Peel HuntReiterated RatingBuy
10/15/2019Peel HuntReiterated RatingBuyGBX 1,280
10/15/2019Peel HuntLower Price TargetBuyGBX 1,390 ➝ GBX 1,280
10/7/2019Peel HuntReiterated RatingBuy
9/30/2019Liberum CapitalInitiated CoverageHoldGBX 1,000
9/19/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/15/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/26/2019Peel HuntReiterated RatingBuyGBX 1,390
6/26/2019Peel HuntReiterated RatingBuyGBX 1,390
6/4/2019Peel HuntReiterated RatingBuy
5/15/2019Peel HuntReiterated RatingBuy
4/2/2019Peel HuntReiterated RatingBuy
3/27/2019Peel HuntReiterated RatingBuy
3/12/2019Peel HuntReiterated RatingBuy
2/27/2019Numis SecuritiesReiterated RatingBuyGBX 1,275
2/27/2019Royal Bank of CanadaReiterated RatingTop pickGBX 1,470 ➝ GBX 1,640
2/27/2019Peel HuntReiterated RatingBuy
2/20/2019Peel HuntBoost Price TargetBuyGBX 1,300 ➝ GBX 1,390
2/13/2019Peel HuntReiterated RatingBuy
2/1/2019Peel HuntReiterated RatingBuy
1/15/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
12/6/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/15/2018Royal Bank of CanadaReiterated RatingTop pickGBX 1,360 ➝ GBX 1,470
10/9/2018Peel HuntLower Price TargetBuyGBX 1,350 ➝ GBX 1,300
10/8/2018Numis SecuritiesReiterated RatingBuyGBX 1,275
10/3/2018Peel HuntReiterated RatingBuy
9/27/2018UBS GroupReiterated RatingBuyGBX 1,160
9/27/2018Peel HuntReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/25/2018Numis SecuritiesReiterated RatingBuy
7/25/2018Peel HuntReiterated RatingBuy
7/17/2018Peel HuntReiterated RatingBuy
7/17/2018Numis SecuritiesReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
5/31/2018Numis SecuritiesUpgradeBuy
5/31/2018Peel HuntReiterated RatingBuy
5/23/2018Berenberg BankReiterated RatingBuyGBX 1,160
4/4/2018Peel HuntReiterated RatingBuy
3/27/2018Berenberg BankLower Price TargetBuyGBX 1,220 ➝ GBX 1,160
3/19/2018Peel HuntReiterated RatingBuyGBX 1,350
2/27/2018Numis SecuritiesReiterated RatingAddGBX 1,208
2/27/2018Peel HuntReiterated RatingBuyGBX 1,350
2/1/2018Peel HuntReiterated RatingBuyGBX 1,350
1/18/2018Berenberg BankUpgradeBuyGBX 1,200 ➝ GBX 1,220
1/17/2018N+1 SingerReiterated RatingBuyGBX 1,225
1/17/2018Numis SecuritiesReiterated RatingAddGBX 1,208
1/17/2018Peel HuntReiterated RatingBuyGBX 1,350
11/29/2017N+1 SingerReiterated RatingBuyGBX 1,225
11/7/2017Royal Bank of CanadaReiterated RatingOutperformGBX 1,360
11/1/2017Berenberg BankInitiated CoverageHoldGBX 1,200
10/31/2017Peel HuntReiterated RatingBuyGBX 1,350
10/10/2017Peel HuntUpgradeBuyGBX 1,200 ➝ GBX 1,350
9/28/2017Peel HuntReiterated RatingAddGBX 1,200
9/13/2017Peel HuntReiterated RatingAddGBX 1,200
9/5/2017Peel HuntDowngradeAddGBX 1,200
8/23/2017Peel HuntReiterated RatingBuyGBX 1,200
8/17/2017Peel HuntReiterated RatingBuyGBX 1,200
7/18/2017Numis SecuritiesDowngradeAddGBX 1,100
7/7/2017Peel HuntBoost Price TargetBuyGBX 1,015 ➝ GBX 1,200
5/22/2017Numis SecuritiesReiterated RatingBuyGBX 951
5/22/2017Stifel NicolausReiterated RatingBuyGBX 970
4/25/2017Peel HuntReiterated RatingBuy
4/13/2017N+1 SingerReiterated RatingBuyGBX 895
4/4/2017Numis SecuritiesUpgradeBuyGBX 951
4/4/2017Stifel NicolausReiterated RatingBuyGBX 970
3/15/2017Peel HuntReiterated RatingBuyGBX 1,015
3/15/2017N+1 SingerReiterated RatingBuyGBX 895
3/10/2017Numis SecuritiesReiterated RatingBuyGBX 933
2/24/2017Peel HuntBoost Price TargetBuyGBX 1,000 ➝ GBX 1,015
1/25/2017Stifel NicolausBoost Price TargetBuyGBX 800 ➝ GBX 900
1/25/2017Numis SecuritiesReiterated RatingBuyGBX 933
1/25/2017Peel HuntReiterated RatingBuyGBX 1,000
1/25/2017N+1 SingerBoost Price TargetBuyGBX 800 ➝ GBX 895
(Data available from 12/5/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Clinigen Group logo
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More

Today's Range

Now: GBX 782
Low: 760
High: 785.50

50 Day Range

MA: GBX 622.08
Low: 576.50
High: 782

52 Week Range

Now: GBX 782
Low: 541.50
High: 891.79


1,549,854 shs

Average Volume

614,836 shs

Market Capitalization

£1.04 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Clinigen Group?

The following Wall Street research analysts have issued stock ratings on Clinigen Group in the last twelve months: Liberum Capital, Peel Hunt, Peel Hunt LLP, Royal Bank of Canada, and Shore Capital.
View the latest analyst ratings for CLIN.

What is the current price target for Clinigen Group?

4 Wall Street analysts have set twelve-month price targets for Clinigen Group in the last year. Their average twelve-month price target is GBX 740, suggesting a possible downside of 5.4%. Royal Bank of Canada has the highest price target set, predicting CLIN will reach GBX 860 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 650 for Clinigen Group in the next year.
View the latest price targets for CLIN.

What is the current consensus analyst rating for Clinigen Group?

Clinigen Group currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLIN will outperform the market and that investors should add to their positions of Clinigen Group.
View the latest ratings for CLIN.

What other companies compete with Clinigen Group?

How do I contact Clinigen Group's investor relations team?

Clinigen Group's physical mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company's listed phone number is +44-1283-495010. The official website for Clinigen Group is www.clinigengroup.com.